Voice your opinion on congressional bill HR5133-116 and let lawmakers know your stance with UnPac!

Main Subject: Commerce

Affordable Prescriptions for Patients Through Promoting Competition Act of 2019

This bill prohibits, subject to certain exceptions, the practice of product hopping, which is presumed when a drug manufacturer obtains removal of a drug from the Food and Drug Administration's approved drug list, discontinues a drug, or markets a reformulation of an already approved drug during a certain period after which the manufacturer has been notified that a competing drug manufacturer has applied for generic drug approval.

S1416-116, HR2486-116, HR4398-116,

House floor actions Actions

Calendars
Dec. 24 2020	Placed on the Union Calendar, Calendar No. 578.

Committee
Dec. 24 2020	Reported by the Committee on Judiciary. H. Rept. 116-695.

IntroReferral
Nov. 18 2019	Referred to the House Committee on the Judiciary.

Library of Congress Actions

Committee
Dec. 24 2020	Reported by the Committee on Judiciary. H. Rept. 116-695.

IntroReferral
Nov. 18 2019	Introduced in House Introduced in House

House committee actions Actions

Committee
Nov. 21 2019	Ordered to be Reported. Committee Consideration and Mark-up Session Held.
Nov. 19 2019	Subcommittee on Antitrust, Commercial, and Administrative Law Discharged.
Nov. 18 2019	Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.

House bill HR5133-116

Affordable Prescriptions for Patients Through Promoting Competition Act of 2019

Promote the cause!

Or use this QR code